Francois P Duhoux

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4995354/publications.pdf

Version: 2024-02-01

57	2,158	471371 17	233338 45
papers	citations	h-index	g-index

58	58	58	3783
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. Clinical Cancer Research, 2022, 28, 106-115.	3.2	18
2	Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. European Journal of Cancer, 2022, 164, 39-51.	1.3	8
3	Abstract PD5-06: Safety of assisted reproductive technologies (ART) following treatment completion in young women with germline BRCA pathogenic variants having a pregnancy after breast cancer. Cancer Research, 2022, 82, PD5-06-PD5-06.	0.4	0
4	MitoQ Prevents Human Breast Cancer Recurrence and Lung Metastasis in Mice. Cancers, 2022, 14, 1488.	1.7	11
5	Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer. European Journal of Cancer, 2022, 166, 300-308.	1.3	11
6	BRCA1 Mutation: An Insidious Enemy with Multiple Facetsâ€¦. Case Reports in Oncology, 2022, 15, 238-244.	0.3	1
7	Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases. JAMA Oncology, 2022, , .	3.4	11
8	Phase I Trial of ¹³¹I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients. Journal of Nuclear Medicine, 2021, 62, 1097-1105.	2.8	67
9	Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants. Npj Breast Cancer, 2021, 7, 16.	2.3	13
10	Tumor apelin and obesity are associated with reduced neoadjuvant chemotherapy response in a cohort of breast cancer patients. Scientific Reports, 2021, 11, 9922.	1.6	10
11	BrainStorm: A brain metastases research platform to tackle the challenge of central nervous system (CNS) metastases in solid tumors (Oncodistinct 006).. Journal of Clinical Oncology, 2021, 39, TPS2066-TPS2066.	0.8	0
12	Assessment of potential process quality indicators for systemic treatment of breast cancer in Belgium: a population-based study. ESMO Open, 2021, 6, 100207.	2.0	3
13	Hypnosis Sedation Reduces the Duration of Different Side Effects of Cancer Treatments in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. Cancers, 2021, 13, 4147.	1.7	6
14	A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptorâ€“Positive Breast Cancer. Clinical Cancer Research, 2021, 27, 5760-5770.	3.2	25
15	FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer. Npj Breast Cancer, 2021, 7, 125.	2.3	9
16	Morphological intratumor heterogeneity in ductal carcinoma in situ of the breast. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 33-43.	1.4	1
17	Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer. BMC Cancer, 2021, 21, 1204.	1.1	2
18	Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer. ESMO Open, 2021, 6, 100300.	2.0	9

#	Article	IF	Citations
19	Neutropenia management in patients receiving myelosuppressive polychemotherapy for early breast cancer in Belgium: BRONS study results. Acta Clinica Belgica, 2020, 75, 128-135.	0.5	3
20	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine, 2020, 382, 597-609.	13.9	789
21	Predictive markers for pathological complete response after neo-adjuvant chemotherapy in triple-negative breast cancer. Annals of Diagnostic Pathology, 2020, 49, 151634.	0.6	13
22	Characterization of Preoperative, Postsurgical, Acute and Chronic Pain in High Risk Breast Cancer Patients. Journal of Clinical Medicine, 2020, 9, 3831.	1.0	8
23	148P Surgery (Sx) of the primary tumour in de novo metastatic breast cancer (BC) patients (pts) is associated with increased survival: AÂnationwide population-based study by the Belgian Cancer Registry (BCR) and the Belgian Society of Medical Oncology (BSMO). Annals of Oncology, 2020, 31, S69.	0.6	0
24	Interobserver Variability in Ductal Carcinoma In Situ of the Breast. American Journal of Clinical Pathology, 2020, 154, 596-609.	0.4	17
25	Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families. Breast Cancer Research, 2020, 22, 36.	2.2	6
26	Impact of Perioperative Hypnosedation on Postmastectomy Chronic Pain: Preliminary Results. Integrative Cancer Therapies, 2019, 18, 153473541986949.	0.8	6
27	A critical appraisal of quality indicators of breast cancer treatment in Belgium. Annals of Oncology, 2019, 30, v75.	0.6	0
28	Intraoperative ketorolac in high-risk breast cancer patients. A prospective, randomized, placebo-controlled clinical trial. PLoS ONE, 2019, 14, e0225748.	1.1	20
29	METASTATIC BREAST CANCER: OPTIMAL IMAGING TECHNIQUES FOR BONE ONLY DISEASE. Breast, 2019, 48, S31-S32.	0.9	0
30	The advantages of hypnosis intervention on breast cancer surgery and adjuvant therapy. Breast, 2018, 37, 114-118.	0.9	36
31	Neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer: The phase II NeoRHEA trial. Annals of Oncology, 2018, 29, viii57.	0.6	0
32	UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer. European Journal of Cancer, 2018, 103, 184-194.	1.3	6
33	Prevalence of pathogenic variants and variants of unknown significance in patients at high risk of breast cancer: A systematic review and meta-analysis of gene-panel data. Critical Reviews in Oncology/Hematology, 2018, 132, 138-144.	2.0	26
34	Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Annals of Oncology, 2018, 29, 2334-2340.	0.6	97
35	Combination of paclitaxel and a LAG-3 fusion protein (eftilagimod alpha), as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Final results from the run-in phase of a placebo-controlled randomized phase II.. Journal of Clinical Oncology, 2018, 36, 1050-1050.	0.8	12
36	Phase I results of CAM-H2: Safety profile and tumor targeting in patients.. Journal of Clinical Oncology, 2018, 36, e13017-e13017.	0.8	6

#	Article	IF	Citations
37	A Standard Set of Value-Based Patient-Centered Outcomes for Breast Cancer. JAMA Oncology, 2017, 3, 677.	3.4	167
38	Comment on â€œIncreased Identification of Candidates for High-Risk Breast Cancer Screening Through Expanded Genetic Testingâ€. Journal of the American College of Radiology, 2017, 14, 582.	0.9	8
39	Combination of paclitaxel and LAG3-Ig (IMP321), a novel MHC class II agonist, as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Interim results from the run-in phase of a placebo controlled randomized phase II.. Journal of Clinical Oncology, 2017, 35, 1062-1062.	0.8	10
40	Routine use of gene panel testing in hereditary breast cancer should be performed with caution. Critical Reviews in Oncology/Hematology, 2016, 108, 33-39.	2.0	17
41	Window of opportunity studies: Do they fulfil our expectations?. Cancer Treatment Reviews, 2016, 43, 50-57.	3.4	37
42	Phase I Study of ⁶⁸Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma. Journal of Nuclear Medicine, 2016, 57, 27-33.	2.8	317
43	Clinical relevance of 8q23, 15q13 and 18q21 SNP genotyping to evaluate colorectal cancer risk. European Journal of Human Genetics, 2016, 24, 99-105.	1.4	17
44	Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application. PLoS ONE, 2016, 11, e0148957.	1.1	9
45	The closely related rare and severe acute myeloid leukemias carrying EVI1 or PRDM16 rearrangements share singular biological features. Haematologica, 2015, 100, e114-e115.	1.7	7
46	Somatic Uniparental Isodisomy Explains Multifocality of Glomuvenous Malformations. American Journal of Human Genetics, 2013, 92, 188-196.	2.6	71
47	Perioperative ketorolac in high risk breast cancer patients. Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial. Medical Hypotheses, 2013, 81, 707-712.	0.8	24
48	Tamoxifen and Ovarian Function. PLoS ONE, 2013, 8, e66616.	1.1	26
49	PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies. British Journal of Haematology, 2012, 156, 76-88.	1.2	48
50	Novel head-to-head gene fusion of MLL with ZC3H13 in a JAK2 V617F-positive patient with essential thrombocythemia without blast cells. Leukemia Research, 2012, 36, e27-e30.	0.4	3
51	The t(11;19)(q23;p13) fusing MLL with MYO1F is recurrent in infant acute myeloid leukemias. Leukemia Research, 2011, 35, e171-e172.	0.4	17
52	Novel variant form of t(11;22)(q23;q13)/MLL-EP300 fusion transcript in the evolution of an acute myeloid leukemia with myelodysplasia-related changes. Leukemia Research, 2011, 35, e18-e20.	0.4	6
53	The t(1;9)(p34;q34) fusing ABL1 with SFPQ, a pre-mRNA processing gene, is recurrent in acute lymphoblastic leukemias. Leukemia Research, 2011, 35, e114-e117.	0.4	25
54	Refinement of 1p36 Alterations Not Involving PRDM16 in Myeloid and Lymphoid Malignancies. PLoS ONE, 2011, 6, e26311.	1.1	17

#	Article	IF	Citations
55	KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia. Leukemia, 2010, 24, 1052-1055.	3.3	39
56	Antivascular Therapy for Epithelial Ovarian Cancer. Journal of Oncology, 2010, 2010, 1-16.	0.6	7
57	Colon Cancer: Update on Adjuvant Therapy. Clinical Colorectal Cancer, 2008, 7, 178-183.	1.0	35